There were no significant changes in total body mass, fat mass, or total body water during 8 weeks of RT and supplementation
Early clinical trials and observational reports have produced mixed results, including: Some reports of reduced interest in alcohol or other substances No observed behavioral change in other participants Small sample sizes and short study durations At this time, there is no conclusive evidence supporting GLP-1 medications as treatments for addiction
Are we bypassing any learned lessons by taking quick fixes
3 Strategic Implications Hanmi Pharmaceuticals continues the ongoing global Phase II SBS trial Eli Lilly and Company gains a differentiated late-stage GI asset Potential expansion into multiple future indications Further diversifies Lillys pipeline beyond obesity, oncology and Alzheimers disease The deal also highlights increasing pharmaceutical interest in gut biology beyond the GLP-1 category that has dominated industry investment over the past several years
As always, treatment decisions should be individualized, considering kidney function, comorbidities, adverse-event profile, costs and reimbursement, and patient preferences